Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2008-03-25
2008-03-25
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C514S002600, C514S008100
Reexamination Certificate
active
07347999
ABSTRACT:
A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation/implantation thereof. The composition and methods of the invention enable restoring and/or enhancing the formation of hematopoiectic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and/or their products, genetic conditions resulting in abnormal stem cells and/or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerence, for the prevention of graft-v-host disease. It is mostly important that the compositions and methods of the invention may be applied for the treatment of diseases affecting primarily or secondarily the stromal microenvironment that supports and regulates hematopoiesis. Further provided is a kit for transplantation into a mammal of BMC in admixture with DBM and/or MBM.
REFERENCES:
patent: 5899939 (1999-05-01), Boyce et al.
Lindholm et al., 1982, Clinical Orthopaedrics and Related Research 171:251-255.
Connolly et al., 1995, Clinical Orthopaedics and Related Research 313:8-18.
Armitage, 1994, New England Journal of Medicine 330:827-838.
An, J. et al., Use of Rat cDNA Probe Specific for the Y Chromosome to Detect Male-Derived Cells, (1997), J. Androl. 18 (3) : pp. 289-293 (Exhibit 1).
Bentley, S.A., Close Range Cell: Cell Interaction Required for Stem Cell Maintenance in Continuous Bone Marrow Culture, (1981), Exp Hematol, 9, pp. 303-312 (Exhibit 2).
Brenner, M.K., et al., Graft versus leukemia effects after marrow transplantation in man, (1991), Baillieres CLin Haematol, 4(3) pp. 727-749 (Exhibit 3).
Brochstein, J.A., Bone Marrow Transplantation for Genetic Disorders, Oncology, (1992), 6(3), pp. 51-58 (Exhibit 4).
Buckley, R.H., et al., haploidentical Bone Marrow Stem Cell Transplantation in Human Severe Combined Immunodeficiency, ((1993) Sein Hematol, 30 (4, Suppl 4) pp. 92-101 (Exhibit 5).
Champlin, R., Immunobiology of Bone Marrow Transplantation as Treatment for hematologic malignancies, (1991), Transplant Proc, 23(4) pp. 2123-2127 (Exhibit 6).
Dorshkind, K., Regulation of hemopoiesis by bone marrow stromal cells and their products, (1990), Ann Rev Immunol, 8, pp. 111-137 (Exhibit 7).
El-Badri, N.S., et al., Osteoblasts promote engraftment of allogeneic hematopoietic stem cells, (1998), Exp Hematol, 26, pp. 110-116 (Exhibit 8).
Enright H., et al., Chronic myelogenous leukemia, (1995), Curr Opin Hematol, 2(4) pp. 293-299 (Exhibit 9).
Gidali, J. et al., Blast Colony Forming Cell-Binding Capacity of Bone Marrow Stroma from Myelodysplastic Patients, (1996), Stem Cells, 14(5), pp. 577-583 (Exhibit 10).
Gurevitch, O.A. et al., The Ability of Induced Osteo-Progate Cells to maintain and Rebuild Long-Term Ectopic Osteo-Hematopoietic Foci In vivo, (1990),Int. J. Cell. Clon 8, pp. 130-137 (Exhibit 11).
Gurevitch, O.A., et al., Ability of Hemopoietic Microevnironment in the Induced Bone to Maintain the Proliferative Potential of Early Hemopoietic Precursors, (1993), Stem Cells, 11, pp. 56-61 (Exhibit 12).
Gurevitch, O.A., et al., Transplantation of allogeneic or xenogeneic bone marrow within the donor stromal microenvironment, (1999), Transplantation, 68, pp. 1362-1368 (Exhibit 13).
Gurevitch, O.A., et al., , Hematol Tansfusiol, 34, pp. 43-45, (Exhibit 14).
Hisha H., et al., Successful bone marrow transplantation by bone grafts in chimeric-resistant combination, (1995), Exp Hematol, 23, pp. 347-352 (Exhibit 15).
Ishida, T., et al., Requirement of Donor-Derived Stromal Cells in the Bone Marrow for Successful Allogeneic Bone Marrow Transplantation, (1994), J. Immunol, 152, pp. 3119-3127 (Exhibit 16).
Koijima S., Hematopoietic growth factors and marrow stroma in aplastic anemia, (1998), Int J. Hematol, 68(1), pp. 19-28 (Exhibit 17).
Lazarus, H.M., et al., Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern cooperative Oncology Group (ECOG), (1997), Bone Marrow Transplant, 68(1), pp. 19-28 (Exhibit 18).
Lazarus, H.M., et al., Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use (1995), Bone Marrow Transplantation, 16, pp. 557-564 (Exhibit 19).
Nakagawa T, et al., Prevention of Autoimmune Inflammatory Polyarthritits in Male New Zealand Blank/KN Mice by Transplantation of Bone Marrow Cells plus bone (Stromal Cells), (1993), Arthritis and Rheumatism, 36, pp. 263-268 (Exhibit 20).
O'Flaherty, E., et al., Bone marrow stromal function from patients after bone marrow transplantation, (1995), Bone Marrow transplant, 15, pp. 207-212 (Exhibit 21).
Quinones, R., Hematopoietic Engraftment and Graft Failure After Bone Marrow Transplantation, (1993), American J. Pediatric Hematology/Oncology, 15(1) pp. 3-17 (Exhibit 22).
Reisner, et al., Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells, (1995) Immunol Today, 16, pp. 437-440 (Exhibit 23).
Rowe, J.M., et al., Recommended Guidelines for the Management of Autologous and Allogeneic Bone Marrow Transplantation, (1994), Ann Intern Med., 120(2), pp. 143-158 (Exhibit 24).
Sanhu, J.S., et al., Human hematopoyesis in SCID Mice Implanted with Human Adult Cancellous Bone, (1996), Blood, 88(6) :1973-1982 (Exhibit 25).
Slavin, et al., Control of replase due to minimal residual disease (MRD) by cell-mediated cytokine-activated immunotherapy in conjunction with bone marrow transplantation, (1991), Curr Opin Oncol, 3(2), pp. 254-271 (Exhibit 26).
Slavin, et al., New developments in bone marrow transplantation, (1991), Baillieres Clin Haematol, 4(3), pp. 715-725 (Exhibit 27).
Smith, R., Regulation of Hematopoieses, (1990), Yale J. Biol Med, 63, pp. 371-380 (Exhibit 28).
Sykes, M., et al., Bone marrow transplantaiton as a means of inducing tolerance, (1990), Semin Immunol, 2, pp. 401-417 (Exhibit 29).
Gurevitch Olga
Kurkalli Basan Gowda S.
Prigozhina Tatyana
Slavin Shimon
Cooper & Dunham LLP
Kemmerer Elizabeth C.
Slavin Shimon
White John P.
LandOfFree
Methods of treatment of hematopoietic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment of hematopoietic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment of hematopoietic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2806788